SEC Form SC 13G filed by Geron Corporation
$GERN
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/10/2025 | $1.00 | Sell | Goldman |
| 5/8/2025 | $1.50 | Sector Outperform → Sector Perform | Scotiabank |
| 2/27/2025 | $3.50 → $2.00 | Buy → Neutral | B. Riley Securities |
| 2/26/2025 | Buy → Neutral | H.C. Wainwright | |
| 11/5/2024 | $8.00 | Buy | H.C. Wainwright |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 9/9/2024 | $7.00 | Outperform | Leerink Partners |
| 4/30/2024 | $4.50 | Outperform → Neutral | Robert W. Baird |
4 - GERON CORP (0000886744) (Issuer)
4 - GERON CORP (0000886744) (Issuer)
4 - GERON CORP (0000886744) (Issuer)
4 - GERON CORP (0000886744) (Issuer)
3 - GERON CORP (0000886744) (Issuer)
4 - GERON CORP (0000886744) (Issuer)
S-8 - GERON CORP (0000886744) (Filer)
8-K - GERON CORP (0000886744) (Filer)
10-Q - GERON CORP (0000886744) (Filer)
Goldman resumed coverage of Geron with a rating of Sell and set a new price target of $1.00
Scotiabank downgraded Geron from Sector Outperform to Sector Perform and set a new price target of $1.50
B. Riley Securities downgraded Geron from Buy to Neutral and set a new price target of $2.00 from $3.50 previously
For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu
Submission status for GERON CORP's drug RYTELO (ORIG-1) with active ingredient IMETELSTAT has changed to 'Approval' on 06/06/2024. Application Category: NDA, Application Number: 217779, Application Classification: Type 1 - New Molecular Entity
Seasoned Commercial Hematology and Oncology Leader Harout Semerjian Appointed as President and CEO Achieved $49.0 million in RYTELO® net product revenue in Q2 2025 Phase 3 IMpactMF clinical trial in relapsed/refractory myelofibrosis is over 95% enrolled and expected to be fully enrolled by year-end Company to host conference call and webcast today, August 6, at 8:00 a.m. ET Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the second quarter of 2025 and recent business highlights. In a separate press release today, the Company announced the appointment of H
Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today announced that it will release its second quarter financial results and business highlights before the market opens on Wednesday, August 6, 2025 via press release, which will be available on the Company's website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m. Eastern Time. A live webcast of the conference call and related presentation will be available on the Company's website at www.geron.com/investors/events. An archive of the webcast will be available on the Company's website for 30 days. About Geron Geron i
Reported $39.4 million in RYTELO® (imetelstat) net product revenue in Q1 2025; revenue impacted by inventory dynamics, with Q1 demand relatively flat Granted marketing authorization of RYTELO by the European Commission (EC); planning for commercial launch in select EU countries 2026 Reached approximately 85% enrollment in the Phase 3 IMpactMF clinical trial for treatment of relapsed/refractory myelofibrosis; interim analysis remains expected in 2H 2026 Company to host conference call and webcast today, May 7 at 8:00 a.m. ET Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial
ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O'Farrell to its Board of Directors as an Independent Director and Chair of the Audit Committee, effective immediately. Ms. O'Farrell brings over three decades of industry experience, spanning strategic planning, financial optimization, regulatory compliance and management. "Liz's established track record in large, commercial healthcare organizations with deep experience in global finance and operations will be instrumental as we continue to advance our SpyGlass Drug Delivery Platform into two pivotal Phase 3 tria
Industry veteran brings 30+ years of commercial hematology and oncology experience to help accelerate Geron's next phase of growth Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Harout Semerjian as President and Chief Executive Officer (CEO) and a member of the Board of Directors, effective tomorrow. Mr. Semerjian will succeed Dawn Carter Bir, who has served as Interim President and CEO since March 2025. Ms. Bir will continue in her role on Geron's Board of Directors, where she will contribute her insight and strategic counsel. "Our Board conducted an extens
Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that John "Chip" A. Scarlett, M.D., President, Chief Executive Officer and Chairman, will depart the company on March 31, 2025. While a search for a new Chief Executive Officer with significant commercial experience is underway, the Board of Directors has appointed Board member Dawn Carter Bir as Interim President and Chief Executive Officer, effective immediately. Additionally, Elizabeth G. O'Farrell has been appointed as Chair of the Board. "It has been an honor to serve Geron over the last 14 years and participate in the development
ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O'Farrell to its Board of Directors as an Independent Director and Chair of the Audit Committee, effective immediately. Ms. O'Farrell brings over three decades of industry experience, spanning strategic planning, financial optimization, regulatory compliance and management. "Liz's established track record in large, commercial healthcare organizations with deep experience in global finance and operations will be instrumental as we continue to advance our SpyGlass Drug Delivery Platform into two pivotal Phase 3 tria
Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 522,000 shares of its common stock, consisting of stock options to purchase an aggregate of 348,000 shares of common stock, and restricted stock units ("RSUs") representing an aggregate of 174,000 shares of common stock, to eleven newly hired employees as an inducement material to their acceptance of employment with Geron. The stock options and RSUs were granted on August 15, 2025. The stock options have an exercise price of $1.45 per share, which is equal to the closing price of Geron common stock on the grant date, have a ten-year term
Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that it has granted an equity award in the form of stock options to purchase 11,000,000 shares of common stock to Harout Semerjian, Geron's new President and Chief Executive Officer, as an inducement material to his acceptance of employment with Geron. The stock options were granted on August 7, 2025. The stock options have an exercise price of $1.30 per share, which is equal to the closing price of Geron common stock on the grant date and have a ten-year term. 7,000,000 of the stock options vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary
SC 13G/A - GERON CORP (0000886744) (Subject)
SC 13G/A - GERON CORP (0000886744) (Subject)
SC 13G - GERON CORP (0000886744) (Subject)